Halozyme Therapeutics, Inc. (HALO)

NASDAQ: HALO · Real-Time Price · USD

125.63

+1.09 (0.88%)

At close: Oct 23, 2026, 4:00 PM EDT

124.58

-1.05 (-0.84%)

After-hours: Oct 23, 2026, 7:30 PM EDT

Halozyme Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct '26 Oct 23, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Capitalization	14,259	7,914	6,083	4,882	7,694	5,659
Market Cap Growth	82.27%	30.11%	24.59%	-36.54%	35.96%	-1.84%
Enterprise Value	16,206	8,751	6,951	5,929	8,940	5,722
Last Close Price	125.63	67.30	47.81	36.96	56.90	40.21

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct '26 Oct 23, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	37.15	24.98	13.70	17.34	38.06	14.05
Forward PE	12.62	8.85	10.38	9.77	21.92	17.89
PS Ratio	8.57	5.67	5.99	5.89	11.66	12.76
PB Ratio	99.81	162.13	16.72	58.26	45.31	28.73
P/TBV Ratio	-	-	-	-	-	28.73
P/FCF Ratio	17.69	12.28	12.99	13.08	32.70	18.99
P/OCF Ratio	17.42	12.15	12.70	12.57	32.04	18.90
PEG Ratio	-	0.55	0.55	0.90	0.91	0.46

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct '26 Oct 23, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
EV/Sales Ratio	9.74	6.27	6.85	7.15	13.54	12.91
EV/EBITDA Ratio	15.42	9.75	11.09	14.22	26.60	20.63
EV/EBIT Ratio	17.16	10.72	12.61	17.56	30.89	20.74
EV/FCF Ratio	20.10	13.58	14.84	15.88	37.99	19.20

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct '26 Oct 23, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Debt / Equity Ratio	15.18	44.60	4.14	18.27	9.07	4.47
Debt / EBITDA Ratio	2.05	2.40	2.38	3.59	4.54	3.15
Debt / FCF Ratio	2.70	3.38	3.22	4.10	6.55	2.95
Net Debt / Equity Ratio	13.57	41.68	2.50	14.26	6.94	0.70
Net Debt / EBITDA Ratio	1.85	2.27	1.45	2.87	3.51	0.50
Net Debt / FCF Ratio	2.42	3.16	1.94	3.20	5.01	0.47
Asset Turnover	0.72	0.61	0.54	0.46	0.45	0.53
Inventory Turnover	2.48	1.95	1.77	2.36	2.67	2.04
Quick Ratio	1.99	3.30	6.50	5.07	4.54	7.10
Current Ratio	2.71	4.66	7.80	6.64	5.65	7.91
Return on Equity (ROE)	173.67%	153.59%	198.42%	222.07%	110.23%	231.44%
Return on Assets (ROA)	25.49%	22.24%	18.16%	11.80%	12.28%	20.47%
Return on Invested Capital (ROIC)	32.13%	33.01%	34.44%	20.77%	27.92%	105.98%
Return on Capital Employed (ROCE)	42.30%	34.80%	28.70%	20.80%	16.90%	27.90%

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct '26 Oct 23, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Earnings Yield	2.69%	4.00%	7.30%	5.77%	2.63%	7.12%
FCF Yield	5.65%	8.14%	7.70%	7.65%	3.06%	5.27%
Buyback Yield / Dilution	4.21%	4.26%	3.56%	4.56%	4.21%	-3.77%

SEC Filings: 10-K · 10-Q